Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some mechanism and adverse-reaction statements are supported by the provided label excerpts, but several claims are unsupported or contradict the label’s indicated use (especially claims about European approval, specific patient populations, patent/generic information sources, and discontinuation risks).
Category Scores
Accurate Statements
Sotagliflozin is an inhibitor of SGLT2 and SGLT1.
12.1 Mechanism of Action: “Sotagliflozin is an inhibitor of SGLT2 and SGLT1.”
By inhibiting SGLT2, sotagliflozin reduces renal reabsorption of glucose and sodium.
12.1: “Inhibiting SGLT2 reduces renal reabsorption of glucose and sodium …”
Inhibiting SGLT1 reduces intestinal absorption of glucose and sodium (which likely contributes to diarrhea).
12.1: “Inhibiting SGLT1 reduces intestinal absorption of glucose and sodium which likely contributes to diarrhea.”
Sotagliflozin lowers blood glucose levels by reducing glucose reabsorption.
12.1: “Inhibiting SGLT2 reduces renal reabsorption of glucose …” (label excerpt does not explicitly say “lowers blood glucose,” but the described pharmacologic effect is consistent with the stated reduction of reabsorption).
Common side effects associated with sotagliflozin include diarrhea.
6.1/Table 1: “Diarrhea” reported as an adverse reaction (SOLOIST and SCORED).
Common side effects associated with sotagliflozin include urinary tract infections.
6.1/Table 1: “Urinary tract infection” reported as an adverse reaction.
Common side effects associated with sotagliflozin include genital yeast infections.
5.6 Genital Mycotic Infections and 6.1/Table 1: “Genital mycotic infection.”
A serious risk of sotagliflozin is diabetic ketoacidosis, particularly in individuals with type 1 diabetes.
5.1: “In patients with type 1 diabetes mellitus, INPEFA significantly increases the risk of diabetic ketoacidosis …”
Another serious, less common risk associated with sotagliflozin is Fournier's gangrene (necrotizing fasciitis of the perineum).
5.5: “Reports of necrotizing fasciitis of the perineum (Fournier's Gangrene) … a rare but serious and life-threatening necrotizing infection …”
Sotagliflozin has been studied in the SOLOIST study for patients hospitalized with worsening heart failure (type 2 diabetes population).
14.1 SOLOIST study description: randomized patients with type 2 diabetes admitted for worsening heart failure.
Sotagliflozin has been studied in the SCORED trial for patients with type 2 diabetes at high cardiovascular risk (and CKD).
14.2 SCORED study description: type 2 diabetes mellitus, chronic kidney disease, additional cardiovascular risk factors.
Results of these trials have informed its regulatory approvals.
14.1 and 14.2 describe trials and endpoints; however, the provided excerpts do not explicitly state regulatory approval. This statement is only partially supported (see unsupported/omission).
Unsupported Statements
Sotagliflozin is an oral medication that acts as a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2).
Label excerpt provided includes “INPEFA for oral administration” and “SGLT2 and SGLT1” inhibition, but the exact phrasing “oral medication” is supported by 11 DESCRIPTION; however “sodium-glucose cotransporters 1 and 2” is not explicitly stated in the provided inhibitor description beyond SGLT1/SGLT2 naming. Mechanism supports dual inhibition; oral administration is supported by 11.
Sotagliflozin reduces absorption of dietary glucose.
12.1 states intestinal absorption of glucose is reduced by SGLT1 inhibition, but does not explicitly use the term “dietary glucose.”
Sotagliflozin targets glucose reabsorption directly.
The label describes inhibition of renal reabsorption and intestinal absorption via SGLT inhibition, but does not explicitly use the wording “targets … directly.”
SGLT2 inhibitors like canagliflozin and empagliflozin primarily work in the kidneys.
The provided label excerpt does not mention other drugs or comparative statements.
SGLT1 inhibitors have an effect on both the kidneys and the small intestine.
The provided label excerpt specifies SGLT2 affects renal reabsorption and SGLT1 affects intestinal absorption; it does not state SGLT1 affects the kidneys.
Sotagliflozin (marketed as Zynquista) has been approved in Europe for the treatment of type 1 diabetes in adults at increased risk of cardiovascular events who have inadequately controlled glycemic status despite optimal insulin therapy.
No European approval or type 1 diabetes indication is supported by the provided label excerpts; 5.1 explicitly states “INPEFA is not indicated for glycemic control.”
Sotagliflozin is indicated for the treatment of heart failure in adults with or without type 2 diabetes.
Provided label excerpt for INPEFA indications is for adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors; it does not support “with or without type 2 diabetes.”
Information regarding sotagliflozin patent expiration dates may be found on DrugPatentWatch.com.
Patent expiration/source claim is not supported by the provided prescribing information excerpts.
Patents typically grant exclusive rights to market and sell a drug for a period of 20 years from the filing date.
General patent-duration statements are not supported by the provided prescribing information excerpts.
After patent expiry, generic or biosimilar versions can enter the market, potentially lowering prices.
Generic/biosimilar entry and pricing-impact statements are not supported by the provided prescribing information excerpts.
Availability of generic versions of sotagliflozin depends on expiration of its patents and any associated market exclusivity periods.
Not supported by provided prescribing information excerpts.
Detailed patent information and predicted generic entry dates for sotagliflozin are available on DrugPatentWatch.com.
Not supported by provided prescribing information excerpts.
Sotagliflozin was jointly developed by Sanofi and Lexicon Pharmaceuticals.
No development-history statements are supported by the provided prescribing information excerpts.
Sotagliflozin's dual SGLT1/SGLT2 inhibition differentiates it from other SGLT2 inhibitors that target only SGLT2.
Comparative statements about other SGLT2 inhibitors are not supported by provided label excerpts.
Sotagliflozin's mechanism offers a novel approach compared to traditional therapies for heart failure.
No such comparative “novel approach/traditional therapies” statement is supported in the provided label excerpts; 12.1 states cardiovascular benefits mechanism “has not been established.”
Discontinuing sotagliflozin, especially in individuals with heart failure or inadequately controlled type 1 diabetes, could lead to worsening of their condition.
The provided label excerpts do not contain discontinuation/worsening risk language, and INPEFA is not indicated for glycemic control (5.1).
For heart failure patients, discontinuing sotagliflozin might increase symptoms or hospitalizations.
Not supported by provided label excerpts.
For type 1 diabetes patients, discontinuing sotagliflozin could result in poorer glycemic control and an increased risk of diabetes-related complications.
Not supported by provided label excerpts; 5.1 states INPEFA is not indicated for glycemic control and focuses on ketoacidosis risk in type 1 diabetes.
The specific risk of lower limb amputations for sotagliflozin is under continued evaluation.
No amputations risk or “under continued evaluation” statement is included in the provided label excerpts.
Some SGLT2 inhibitors have an associated potential risk of lower limb amputations.
Not supported by provided label excerpts.
Sotagliflozin lowers blood glucose levels by reducing glucose reabsorption.
Mechanism indicates reduced glucose reabsorption, but the excerpt does not explicitly claim “lowers blood glucose levels.”
Contradictions
Low
AI Statement
Sotagliflozin is indicated for the treatment of heart failure in adults with or without type 2 diabetes.
Label Reference
1 INDICATIONS AND USAGE and 5.1: Provided indication is for adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors; 5.1 also states INPEFA is not indicated for glycemic control. The specific “with or without type 2 diabetes” phrasing is not supported and conflicts with the label’s stated required conditions.
Important Omissions
Dosage and administration details (dose, titration schedule, when to withhold/resume) are not evaluated because the AI response did not provide dosing/administration claims. If the AI response intended to discuss dosing, the label sections under Dosage and Administration were not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/misaligned claims about indication populations (including type 1 diabetes Europe approval and broad heart-failure use “with or without type 2 diabetes”) and lack of label-supported discontinuation risk messaging could lead to inaccurate clinical interpretation relative to the provided label. Some safety mechanisms (DKA in type 1, Fournier’s gangrene, genital mycotic infections) are aligned.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Key indication/population claims are not supported by the provided label excerpts, including an asserted type 1 diabetes approval and broad “heart failure with or without type 2 diabetes” indication wording.
Suggested Improvement
Limit claims to the provided INPEFA indications (reduce risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with the specified heart failure/type 2 diabetes + chronic kidney disease + other cardiovascular risk factors) and remove/avoid non-label patent/generic-source and discontinuation-risk assertions.